Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Anderson-Type Manganese Polyoxomolybdate Hybrid Nanocomposite for Boosting Drug Delivery Against Breast Cancer Publisher

Summary: Research shows manganese-based nanocomposites kill breast cancer cells effectively, with low toxicity to healthy cells. #CancerResearch #Nanotechnology

Mahvash S1 ; Zavareh VA2 ; Taymouri S3 ; Mirian M4 ; Ramezanialiakbari M5 ; Dousti F6 ; Rostami M7
Authors

Source: Journal of Drug Delivery Science and Technology Published:2023


Abstract

Novel biocompatible nanocomposites (NCs) of Anderson-type manganese polyoxomolybdate (MnMo6) in chitosan imidazolium platform (MnMo6@CSIm NCs) were introduced for modulating cytotoxicity profile. The anticancer activity of optimized NCs was evaluated against breast cancer cell lines (MCF-7 & MDA-MB-231) and HUVEC normal cells using the MTT assay. Cellular uptake, apoptosis ratio, and cell migration inhibition were also evaluated on the MDA-MB-231 cell line. The optimized pH-responsive NCs had better anticancer activity than free MnMo6 without cytotoxicity against normal HUVEC cells. The cellular uptake was about 100%, and the apoptosis value was higher (81%) than free MnMo6. Interestingly, the MnMo6@CSIm NCs inhibited the cell migration 1.5 times better than the free MnMo6. These results are fascinating to follow more pre-clinical studies. © 2023 Elsevier B.V.
Other Related Docs
4. Arsenic Polyoxotungstate-Zeolitic Imidazolate Framework-8 As a Potential Selective Anti-Cancer Nano Platform, Journal of Inorganic and Organometallic Polymers and Materials (2023)
6. Novel Tocopherol Succinate-Polyoxomolybdate Bioconjugate As Potential Anti-Cancer Agent, Journal of Inorganic and Organometallic Polymers and Materials (2021)
9. Anti-Cancer Activity of Biotin-Polyoxomolybdate Bioconjugate, Eurasian Journal of Medicine and Oncology (2020)
18. Co-Delivery of Stat3 Sirna and Methotrexate in Breast Cancer Cells, Artificial Cells, Nanomedicine and Biotechnology (2022)